European Atherosclerosis Society

👉 The REPRIEVE trial demonstrated significant benefits of pitavastatin in reducing cardiovascular risk for people with HIV (PWH), but the findings need nuanced interpretation due to the unique characteristics of the population studied: 1️⃣ HIV and CV Risk Assessment PWH face 2x the cardiovascular (CV) risk of the general population. This makes standard CV risk assessment tools, like the Pooled Cohort Equations, suboptimal for estimating baseline risk in this group. The combination of traditional and HIV-specific risk factors (inflammation, immune activation) demands tailored approaches for accurate risk stratification 2️⃣ Population Characteristics The trial population was predominantly male (85%), with notable risk factors for a “low/moderate risk” cohort: 10% had coronary artery calcium (CAC) >100, indicating significant subclinical atherosclerosis. 25% were current smokers, a major risk factor for CV events. 20% had hypertension, with a mean BMI of 27, edging into the overweight category. These characteristics suggest that many participants might have been at higher-than-advertised baseline risk. Does this truly reflect a low-to-moderate risk population? 3️⃣ hsCRP and Inflammation The use of high-sensitivity C-reactive protein (hsCRP) as an inflammatory biomarker continues to show limited predictive value in HIV and CV risk settings. Despite being a marker of systemic inflammation, its utility in guiding therapy or predicting outcomes appears inconsistent, especially in well-treated PWH. 👆 The study’s results are promising for pitavastatin but raise important questions about generalizability, baseline risk definition, and the role of inflammation biomarkers in managing CV risk in PWH. European Atherosclerosis Society

The availability of more options for #lipid-lowering medication poses new challenges to decision-making in clinical practice. Especially, as according to current #guidelines, patients are recommended to be involved in the decision-making process. Therefore we explored the preferences and experiences with #PCSK9 inhibitors (#PCSK9i) among patients and healthcare providers Our main findings were: 👉 Efficacy is the primary consideration for patients and healthcare professionals when determining the need for add-on PCSK9i therapy 👉 90% of the patients prefer shared decision-making 👉 Only 27% of the healthcare professionals consider patient preferences when prescribing a PCSK9i Our findings underscore the necessity for a decision aid to facilitate shared decision-making regarding PCK9i therapy for both healthcare professionals and patients. https://lnkd.in/ed6vwMxw #AtherosclerosisJournal #ATHJournal Janneke Mulder Leonieke Kranenburg Ken Redekop Annette Galema-Boers PhD European Atherosclerosis Society

This 📑 summarizes our current understanding on minor SPBs and the role of the SPT in particular of its subunits SPTLC3 and SPTSSA/B in forming a spectrum of structurally and metabolically distinct SPBs 🔗 https://lnkd.in/gJk398MB #AtherosclerosisJournal #ATHJournal

• Fat accumulation in the liver sets the ground for disease development and progression • Lipotox is one of the major phenomena associated w/ MASLD path • Different type of lipids may trigger different effects during MASLD, exerting cell-specific effects 🔗 https://lnkd.in/dtxp26UZ #AtherosclerosisJournal #ATHJournal

What if we told you the best-kept secrets are just one click away? The newest issue of our newsletter is here, and trust us - it’s not what you think. Discover it yourself: https://lnkd.in/dKM-yntG

👉 From cardiorenal to cardiovascular–kidney–metabolic syndromes 👆 What began in ancient times as hints of connections between the heart and kidneys1has evolved into CRS and CKM, two common and related syndromes. While both can be recognized and often treated, much more must be learned about these syndromes and their prevention is now an important goal. 🔓 Open Access https://lnkd.in/dsT_KMJS European Atherosclerosis Society

Secure your place at #EASCongress2025 and be part of the global conversation. Register to benefit from exclusive early-bird rates: https://bit.ly/3UYJAKF #CardiovascularHealth #Cardiovascular #AtherosclerosisResearch #HeartHealthExperts

In 👫 with pseudoxanthoma elasticum without manifest CVD, there is a significant, independent, association between the level of arterial calcification and the risk of a future 🫀 event 🔗 https://lnkd.in/eKnMY6VP #AtherosclerosisJournal #ATHJournal

CVDs develop over a lifetime, making early prevention crucial. Adopting health-promoting behaviors such as a balanced diet and active lifestyle is key. Along with regular physical activity, avoiding smoking, and limiting alcohol, it’s important to reduce animal-based foods and those high in salt, sugar, and fat. Increasing the intake of fruits, vegetables, legumes, grains, and nuts supports a heart-healthy, plant-based diet. Start early, live healthy! Read our latest joint partner article: https://eas.to/DHArt7_2024

• ⬆️ LDL-C for p.Ser127Arg than for other PCSK9-GOFVs carriers, suggesting a stronger hypercholesterolemic potential • ⬇️ HDL-C for p.Ser127Arg than for other PCSK9-GOFVs carriers, supporting the PCSK9/ HDL metabolism association 🔗 https://lnkd.in/dRXEJDB6 #AtherosclerosisJournal #ATHJournal